A gentler way to harvest bypass veins did not cut heart events at seven years

When surgeons perform a coronary artery bypass, they often use a length of the patient's own saphenous vein from the leg to route blood around a blocked artery. These vein grafts are workhorses, but they have a weakness: a meaningful share clog up within a few years. One proposed fix is a gentler harvesting method called "no-touch," in which the vein is removed with a cuff of surrounding tissue still attached, rather than being stripped bare and distended. Earlier imaging studies suggested no-touch veins stay open more often. The SWEDEGRAFT trial asked the harder question — whether that translates into fewer bad outcomes for patients — and the seven-year answer is no [s1].

What the trial did

SWEDEGRAFT was an academic, investigator-led, randomised trial sponsored by Uppsala University and run at eight cardiac surgery centres in Sweden and one in Denmark [s1][s2]. It enrolled adults undergoing a first, non-emergency, isolated bypass operation and randomly assigned them 1:1 to either no-touch or conventional saphenous vein harvesting [s1]. In all, 902 patients were randomised, with 900 included in the main analysis — 454 in the no-touch group and 446 in the conventional group [s1]. Their mean age was 67.0 years, 12.0% were women, and 46.6% had non-elective surgery [s1]. The original operations took place between April 2018 and June 2020 [s1]. The primary outcome was a composite of death from any cause, heart attack, or repeat revascularisation, tracked through national health registries rather than by in-person study visits — a register-based design that keeps follow-up near-complete but relies on administrative coding to capture events [s1]. This report extended follow-up to a median of 6.46 years, with an interquartile range of 5.92 to 6.86 years, making it one of the longer looks at the two harvesting techniques head to head [s1].

What it found

The two techniques came out even. The primary composite occurred in 90 no-touch patients and 91 conventional patients — 19.8% versus 20.4% — for a hazard ratio of 0.98 (95% confidence interval 0.73 to 1.31) and a P value of 0.90 [s1]. The adjusted difference in seven-year risk was -0.8%, with a confidence interval running from -6.6% to 4.6% that comfortably straddles zero [s1]. None of the individual components separated the groups either: the hazard ratio was 0.84 (95% CI 0.53 to 1.35) for death, 0.74 (0.44 to 1.24) for heart attack, and 1.07 (0.73 to 1.56) for repeat revascularisation [s1]. Pre-specified subgroup analyses showed no group that clearly benefited [s1].

How to read it

This is a clean null result, and its value lies partly in the gap it closes between a surrogate and an outcome. No-touch harvesting really does appear to keep more grafts anatomically open on angiography, which is why the technique has supporters. But graft patency is a stand-in for what patients actually care about — staying alive and out of the catheterisation lab — and SWEDEGRAFT shows that the imaging advantage did not carry through to those endpoints over seven years [s1]. A surgical technique can look better on a scan and make no measurable difference to how a cohort of patients fares. It is a pattern seen repeatedly across medicine, and it is the reason trials that track patient outcomes, not just images, remain the standard of proof.

Two caveats cut in opposite directions. The trial was not blinded, which is unavoidable in surgery and matters less for hard registry-based endpoints like death than for softer judgments [s1]. And with roughly 180 events, the confidence interval is wide enough that a modest benefit or harm cannot be formally excluded — the data rule out a large effect, not a small one [s1]. Against that, no-touch harvesting is not free: the technique leaves a larger leg wound, and the investigators note it carried an excess of leg-wound complications reported earlier in the trial [s1]. A procedure that adds a known downside while delivering no measurable clinical upside is hard to justify as a routine default. For an individual patient, the calculus may still differ — a surgeon weighing graft durability against wound risk in a younger patient facing decades of follow-up might reason differently — but as a population-level policy, the trial gives no support to switching everyone to no-touch harvesting.

Related coverage has examined a 15-year comparison of arterial bypass graft strategies and how a vein-graft preservation solution reached the market.

What to watch

SWEDEGRAFT does not close the book on graft biology — researchers will keep probing why open grafts do not reliably translate into better survival, and whether specific patients might still benefit from no-touch harvesting [s1]. For now, the trial is a useful corrective to the assumption that a technique with better angiographic numbers must be better for patients.

This article describes research and is not medical advice. Surgical decisions are a matter for patients and their cardiac surgical teams.

Sources

• No-Touch vs Conventional Vein Grafts in Coronary Surgery: Seven-Year Clinical Outcomes of SWEDEGRAFT — JAMA Cardiology, 30 September 2026
• SWEDEGRAFT trial registration (NCT03501303) — ClinicalTrials.gov